Jerald P. Radich MD

Jerald P. Radich, MD, is Director of the Molecular Oncology Lab and Professor of the Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center, where he holds the position of Kurt Enslein Endowed Chair. He also is a Professor in the Division of Medical Oncology at University of Washington School of Medicine.

Dr. Radich earned a master's of science degree in epidemiology at Harvard University School of Public Health before attending University of California Davis School of Medicine. He completed both his internship and residency in internal medicine at University of Washington Affiliated Hospitals before accepting a position as chief medical resident at the Veterans Administration Medical Center Affiliated Hospitals in Seattle, Washington. Dr. Radich then took a fellowship in medical oncology at Fred Hutchinson Cancer Center, where he subsequently has remained.

Dr. Radich specializes in the genetics of leukemia and the use of modern molecular biology techniques toward the early detection of cancer. His laboratory research focuses on the molecular biology of response, resistance, and progression in hematological malignancies. His team studies how specific genetic variants influence treatment outcomes in order to develop new drugs and improve decision-making for individualized patient care.

Dr. Radich is Chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group and a member of the European LeukemiaNet (ELN) Chronic Myeloid Leukemia (CML) Panel. He also serves on the Scientific Board for the International CML Foundation and the Max Foundation, a global health nonprofit organization dedicated to accelerating health equity. He currently leads the Laboratory Committee of the National Cancer Institute's (NCI)Acute Myeloid Leukemia (AML) Precision Medicine Initiative and the NIH's Program in measurable residual disease in AML. He was the inaugural Chair of the NCI/NIH Leukemia Steering Committee and previously served on the Board of Scientific Counselors of the NIH Genome Research Institute. He is past-Chair of the CML Guidelines Panel for the National Comprehensive Cancer Network.